COCP - Pangali EV/EBITDA Cocrystal Pharma

This price chart on GURU.Markets demonstrates that Cocrystal Pharma, Inc. (COCP) has an EV/EBITDA multiple of 0.00. Cocrystal Pharma, Inc. (COCP) holds recognized status in developing antiviral agents, utilizing advanced crystallography to combat pandemic threats. The technology stack relies on AI simulations and robotics, which automates the search for new formulas. Despite a narrow specialization in treating influenza and COVID, risks are mitigated by a robust patent portfolio.

For Cocrystal Pharma, Inc. (COCP), which is vulnerable to logistical disruptions and patent risks, the EV/EBITDA multiple serves as a tool to verify the adequacy of market value relative to operating profit before taxes, depreciation, and amortization. Analyzing this ratio allows an investor to determine the extent of the premium paid for the asset by assessing how effectively the business generates cash flow to cover total debt and capitalization.